Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Health Committee roster

Executive Summary

New members of the Senate Health Committee are unlikely to support legislation favoring the brand industry. Senator-elect Bernie Sanders (I-Vt.), a strong supporter of drug importation, described himself during his campaign as "one of the national leaders in opposing the pharmaceutical industry - the greediest industry in the country." Sen. Barack Obama (D-Ill.), who has also supported importation, will also join the committee (1"The Pink Sheet" Nov. 8, 2004, p. 5). As expected, Senator-elect Sherrod Brown (D-Ohio) will be the other addition to the committee; the congressman has a history of supporting generic drug issues (2"The Pink Sheet" Nov. 13, 2006, p. 3)...

You may also be interested in...

Democratic Capitol Hill Will Create Challenges For Brand Industry

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

GOP Victory Won’t End Rx Import Debate: New Senators Want Open Borders

Seven of the nine new Senators who will join the chamber in January have professed their support for importing prescription drugs into the U.S

ATOM Coalition Seeks Partners To Create New Oncology Markets

The ATOM Coalition is seeking partners in the generics and biosimilars industry to help create new markets for cancer medicines in LLMICs.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts